Expression and Significance of PD-1, PD-L1 and PD-L2 in T Cell Subsets and Myeloma Cells in Newly Diagnosed Multiple Myeloma Patients

MA Yinjuan; YANG Ke; YANG Xiaying; BAI Jiaofeng; BAI Hai; WU Tao; FU Lihua; JIANG Junfeng; PAN Yaozhu

doi:10.3971/j.issn.1000-8578.2022.21.0352

Cancer Research on Prevention and Treatment > 2022 > 49(1): 40-45. > DOI: 10.3971/j.issn.1000-8578.2022.21.0352

MA Yinjuan, YANG Ke, YANG Xiaying, BAI Jiaofeng, BAI Hai, WU Tao, FU Lihua, JIANG Junfeng, PAN Yaozhu. Expression and Significance of PD-1, PD-L1 and PD-L2 in T Cell Subsets and Myeloma Cells in Newly Diagnosed Multiple Myeloma Patients[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 40-45. DOI: 10.3971/j.issn.1000-8578.2022.21.0352

Citation:

PDF ( 0 KB)

Expression and Significance of PD-1, PD-L1 and PD-L2 in T Cell Subsets and Myeloma Cells in Newly Diagnosed Multiple Myeloma Patients

1.
Department of Hematology, The 940th Hospital of Joint Support Force of Chinese People's Liberation Army, Lanzhou 730050, China
2.
Graduate School of Ningxia Medical University, Yinchuan 750004, China
3.
Department of Hematology, Gansu Provincial Cancer Hospital, Lanzhou 730050, China

Funding:

Gansu Province Health Industry Research Project GSWSKY-2019-63

Grant-in-aid from the PLA Logistics Research Project CLB19J047

More Information

Corresponding author:
PAN Yaozhu, E-mail : panyaozhu@163.com
Received Date: March 28, 2021
Revised Date: July 18, 2021
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the expression of PD-1 and PD-L1/2 in T cell subsets and myeloma cells in the bone marrow from newly diagnosed multiple myeloma (NDMM) patients and their relation with clinical features.
Methods
We collected the bone marrow and clinical data of 22 NDMM patients and 18 cases of healthy controls. We sorted CD4⁺T cells, CD8⁺T cells and myeloma cells by flow cytometry, and observed the expression of PD-1 and PD-L1/2.
Results
Compared with the control group, the proportion of CD8⁺T cells in the NDMM group was significantly higher, while the ratio of CD4⁺/CD8⁺ was significantly lower (both P < 0.05). The expression levels of PD-1 and PD-L2 in CD4⁺T cells in the NDMM group were significantly higher than those in the control group (both P < 0.05). The expression levels of PD-1, PD-L1 and PD-L2 in T cell subsets and myeloma cells of NDMM patients were not correlated with the gender, age, immune typing, Durie-Salmon stage and subtypes, ISS stage or mSMART3.0 stratification (both P > 0.05).
Conclusion
Most of MM patients suffering immune abnormality, which may be associated with the mutual immunosuppressive effects between T lymphocytes and plasma cells which expressing PD-1 and PD-L1/2.
- Multiple myeloma,
- Programmed death receptor-1,
- Programmed death ligand-1,
- Programmed death ligand-2

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (16)

References

[1]	Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma[J]. BMJ, 2020, 370: m3176.
[2]	Costa F, Marchica V, Storti P, et al. PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression[J]. Cancers (Basel), 2021, 13(2): 164. doi: 10.3390/cancers13020164
[3]	Guo S, Xiao P, Li B, et al. Co-immunizing with PD-L1 induces CD8⁺ DCs-mediated anti-tumor immunity in multiple myeloma[J]. Int Immunopharmacol, 2020, 84: 106516. doi: 10.1016/j.intimp.2020.106516
[4]	Korkmaz S, Erdem S, Akay E, et al. Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?[J]. Turk J Med Sci, 2019, 49(1): 265-271.
[5]	马银娟, 杨夏影, 王莹, 等. PD-1/PD-L1/2通路在多发性骨髓瘤中的研究进展[J]. 肿瘤防治研究, 2021, 48(6): 647-651. doi: 10.3971/j.issn.1000-8578.2021.21.0108 Ma YJ, Yang XY, Wang Y, et al. Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma[J]. Zhong Liu Fang Zhi Yan Jiu, 2021, 48(6): 647-651. doi: 10.3971/j.issn.1000-8578.2021.21.0108
[6]	中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2017年修订)[J]. 中华内科杂志, 2017, 56(11): 866-870. doi: 10.3760/cma.j.issn.0578-1426.2017.11.021 Chinese Hematology Association, Chinese Society of Hematology, Chinese Myeloma Committee-Chinese Hematology Association. The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision)[J]. Zhonghua Nei Ke Za Zhi, 2017, 56(11): 866-870. doi: 10.3760/cma.j.issn.0578-1426.2017.11.021
[7]	Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?[J]. Blood, 2017, 129(3): 275-279. doi: 10.1182/blood-2016-08-731885
[8]	Seliger B. Basis of PD1/PD-L1 Therapies[J]. J Clin Med, 2019, 8(12): 2168. doi: 10.3390/jcm8122168
[9]	Cohen AD, Raje N, Fowler JA, et al. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma[J]. Clin Cancer Res, 2020, 26(7): 1541-1554. doi: 10.1158/1078-0432.CCR-19-2111
[10]	Alrasheed N, Lee L, Ghorani E, et al. Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4⁺PD-1⁺ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma[J]. Clin Cancer Res, 2020, 26(13): 3443-3454. doi: 10.1158/1078-0432.CCR-19-1714
[11]	Dosani T, Carlsten M, Maric I, et al. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies[J]. Blood Cancer Journal, 2015, 5(4): e306. doi: 10.1038/bcj.2015.32
[12]	Gu Y, Jin Y, Ding J, et al. Low absolute CD4⁺ T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Lymphoma[J]. Leuk Lymphoma, 2020, 61(8): 1869-1876. doi: 10.1080/10428194.2020.1751840
[13]	Tan J, Chen S, Huang J, et al. Increased exhausted CD8⁺ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma[J]. Asia Pac J Clin Oncol, 2018, 14(5): e266-e274. doi: 10.1111/ajco.13033
[14]	Huang LQ, Wang JX, He K, et al. Analysis of peripheral blood T-cell subsets and regulatory T-cells in multiple myeloma patients[J]. Cell Mol Biol(Noisy-le-grand), 2018, 64(5): 113-117. doi: 10.14715/cmb/2018.64.5.19
[15]	Crescenzi A, Annibali O, Bianchi A, et al. PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma[J]. Leuk Res, 2016, 49: 98-101. doi: 10.1016/j.leukres.2016.09.008
[16]	Wang L, Wang H, Chen H, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma[J]. Oncotarget, 2015, 6(38): 41228-41236. doi: 10.18632/oncotarget.5682

[1]	DENG Changgang, ZHANG Wei, SUN Yanyu, LI Qisui, HUANG Wei, YUAN Jing. Progress of Research on Programmed Death-1/Programmed Death Ligand-1 Inhibitors for HIV/AIDS with Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(9): 924-928. DOI: 10.3971/j.issn.1000-8578.2023.23.0102
[2]	WU Mingzhe, WANG Fuchun, PAN Haojie, ZHOU An'an, XIAO Xi, TIAN Junqiang. Progress of Different Programmed Cell Death Pathways in Kidney Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 531-537. DOI: 10.3971/j.issn.1000-8578.2023.22.1100
[3]	CHANG Jinyi, WANG Wei, CAI Haifeng. Research Progress of PD-1/PD-L1 Inhibitor Combined with Trastuzumab in HER2-positive Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 965-969. DOI: 10.3971/j.issn.1000-8578.2022.21.1462
[4]	YUAN Ting, CAO Zheng, LIU Xiuyun, ZHENG Bo, FENG Xiaoli. Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 941-946. DOI: 10.3971/j.issn.1000-8578.2021.21.0307
[5]	MA Yinjuan, YANG Xiaying, WANG Ying, WANG Xuan, PAN Yaozhu. Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 647-651. DOI: 10.3971/j.issn.1000-8578.2021.21.0108
[6]	WANG Ping, YANG Wenxiu, ZHOU Jie, FENG Jianglong, LIN Chaoqun. Expression of PD-L1 and Its Clinical Significance in MYC/BCL2 Double-expression Large B Cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(1): 32-36. DOI: 10.3971/j.issn.1000-8578.2020.19.0957
[7]	ZHANG Wei, LI Shoumiao, GONG Yanxin, LI Baozhong, ZHANG Zhizhong, LIU Zhiqiang. Expression of Programmed Cell Death 1 and Lymphocyte Activation Gene 3 in Perioperation of Adenocarcinoma of Esophagogastric Junction and Related Significance[J]. Cancer Research on Prevention and Treatment, 2019, 46(5): 436-439. DOI: 10.3971/j.issn.1000-8578.2019.18.1518
[8]	ZHANG Lijun, QI Feng, CHENG Zhiyong, ZHANG Zhao, WU Shijie, GUO Yantao, SUN Li'na, PENG Zhanxian, LIANG Wentong. Effects of Interferon on PD-1/PD-L1 and Treg Expression in JAK2 V617F-positive Myeloproliferative Neoplasms[J]. Cancer Research on Prevention and Treatment, 2019, 46(1): 63-67. DOI: 10.3971/j.issn.1000-8578.2019.18.0937
[9]	ZENG Tianmei, YE Fei, ZHANG Chunyang, FU Weijun, LI Lu, ZHOU Fan, HOU Jian. Impact of 1q21 Amplification on Prognosis of Multiple Myeloma Treated with Bortezomib or Thalidomide[J]. Cancer Research on Prevention and Treatment, 2013, 40(06): 521-524. DOI: 10.3971/j.issn.1000-8578.2013.06.004
[10]	YANG Ying, FENG Hao, JING Xiao-hong, GOU Xing-chun. Rapamycin Induces Cell Death of Hepatoma Cells via Upregulation of Beclin 1[J]. Cancer Research on Prevention and Treatment, 2011, 38(12): 1367-1369. DOI: 10.3971/j.issn.1000-8578.2011.12.007

Cited By

Cited by

Periodical cited type(4)

1.	郭姗琦，孙彬栩，姜行康，杨同，贾英杰，孔凡铭. 健脾利湿化瘀方联合内分泌治疗对转移性激素敏感性前列腺癌的治疗效果. 肿瘤研究与临床. 2024(07): 503-508 .
2.	刘和洋，刘倩，红华，金殿生，高慧敏，包森林，李文. 超声影像组学联合模型预测前列腺癌内分泌治疗无进展生存期的价值. 中华超声影像学杂志. 2024(11): 992-999 .
3.	张涛，王斌，刘一鸿，席国旺，李中学. 微创经尿道前列腺等离子电切术联合去势治疗高龄晚期前列腺癌的临床研究. 青岛医药卫生. 2023(01): 49-52 .
4.	温雪丽. 骨标志物和PSA对前列腺癌发展为CRPC的预测价值. 国际检验医学杂志. 2021(24): 3036-3040 .

Other cited types(8)

Figures(1) / Tables(5)

Get Citation

PDF

XML

Article views (2722) PDF downloads (645) Cited by(12)

Turn off MathJax

Article Contents

Abstract

References

Expression and Significance of PD-1, PD-L1 and PD-L2 in T Cell Subsets and Myeloma Cells in Newly Diagnosed Multiple Myeloma Patients